CRBU
Caribou Biosciences, Inc.
$1.83
+0.01 (+0.55%)
At close · Jul 6
Market Cap
$181.50M
Shares
99,180,575
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.83
Open$1.83
Day$1.80–1.85
52W$1.34–3.54
Avg vol 30d2.2M
Short int7.5M · 7.6% float · 4.2d
Short vol65%
Last earningsMay 7, 2026
DataJul 2021–Jul 2026
Filing10-Q · May 7
Equibles Rating
blended score · not investment advice
Overall
Neutral
Technical · trend & momentum
Sell
◦
50 / 200-day cross
no cross
−
Price vs 200-day avg
−5% below
−
Price vs 50-day avg
−6% below
◦
RSI (14)
51 · neutral
+
MACD trend
positive
◦
52-week position
23% · mid-range
Sentiment · smart money
Neutral
◦
Trend (MA cross)
50d $2 › 200d $2 — 50d above 200d
+
Institutional flow
+10% holders QoQ · +28 funds added
◦
Insider flow
No net insider activity over 90 days
−
Short interest
7.59% of float · ▲ +1.1% MoM · 4.2 days cover
◦
Volume signal
Volume near normal
◦
Institution breadth
137 holders — mid 3-yr range
Fundamentals
Strong
+
Revenue growth
+12% Y/Y
◦
EPS growth
+4% Y/Y
−
Free cash flow
$-112.4M
+
Balance sheet
net cash $12.4M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Aug 16, 2026
Est · unconfirmed
· in 6 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
−5% below
Bearish
Price vs 50-day avg
−6% below
Bearish
RSI (14)
51 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
23% · mid-range
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
+10% holders QoQ · +28 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
7.59% of float · ▲ +1.1% MoM · 4.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
137 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $1
Now $2 · 23%
52-wk high $4
vs 200-day avg -5%
vs 50-day avg -6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CRBU
this stock
Caribou Biosciences, Inc.
|
$181.50M | +15.1% | +11.7% | — | 7.6% |
|
AKTX
Akari Therapeutics Plc
|
$998.08B | -5.7% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$488.96B | +1.9% | +22179.2% | 995.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.41B | +16.8% | +46.2% | 31.4 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.33B | -15.7% | +20.8% | 16.1 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CRBU | +8.9% | -11.4% | +10.2% | +4.0% | +15.1% |
| SPY | +3.1% | -0.8% | +8.2% | +0.6% | +10.2% |
| vs SPY | +5.9% | -10.6% | +2.0% | +3.4% | +4.9% |